Pregnancy complications following prenatal exposure to SSRIs or maternal psychiatric disorders: Results from population-based national register data

American Journal of Psychiatry

Volumn 172, Issue 12, 2015, Pages 1224-1232

  Malm, Heli ^a,b,c,d,e,f   Sourander, Andre ^a,b,c,d,e,f   Gissler, Mika ^a,b,c,d,e,f   Gyllenberg, David ^a,b,c,d,e,f   Hinkka Yli Salomäki, Susanna ^a,b,c,d,e,f   McKeague, Ian W ^a,b,c,d,e,f   Artama, Miia ^a,b,c,d,e,f   Brown, Alan S ^a,b,c,d,e,f  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c Helsinki University ^*  (United States)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e NORDIC SCHOOL OF PUBLIC HEALTH   (Sweden)

^f Department of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ADVERSE OUTCOME; ANXIETY DISORDER; APGAR SCORE; ARTICLE; BIPOLAR DISORDER; CESAREAN SECTION; COHORT ANALYSIS; CONGENITAL MALFORMATION; CONTROLLED STUDY; DEPRESSION; EMOTIONAL DISORDER; FEMALE; FINLAND; FIRST TRIMESTER PREGNANCY; HIGH RISK POPULATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MENTAL DISEASE; MOOD DISORDER; MOTHER; NEWBORN; NEWBORN CARE; POPULATION RESEARCH; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROGENY; PROSPECTIVE STUDY; PSYCHOSIS; SECOND TRIMESTER PREGNANCY; SMALL FOR DATE INFANT; THIRD TRIMESTER PREGNANCY; CHEMICALLY INDUCED; COMPLICATION; MENTAL DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; REGISTER;

ADULT; CESAREAN SECTION; FEMALE; HUMANS; MENTAL DISORDERS; PREGNANCY; PREGNANCY COMPLICATIONS; PREMATURE BIRTH; REGISTRIES; SEROTONIN UPTAKE INHIBITORS;

EID: 84949239283     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.14121575     Document Type: Article

References (37)

1. Malm H, Artama M, Brown AS, et al: Infant and childhood neurodevelopmental outcomes following prenatal exposure to selective serotonin reuptake inhibitors: Overview and design of a Finnish Register-Based Study (FinESSI). BMC Psychiatry 2012; 12:217
2. Cooper WO,Willy ME, Pont SJ, et al: Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007; 196: 544.e1-544.e5
3. El Marroun H, Jaddoe VW, Hudziak JJ, et al: Maternal use of selective serotonin reuptake inhibitors, fetal growth, and risk of adverse birth outcomes. Arch Gen Psychiatry 2012; 69:706-714
4. Reis M, Källén B: Delivery outcome after maternal use of antidepressant drugs in pregnancy: An update using Swedish data. Psychol Med 2010; 40:1723-1733
5. Lund N, Pedersen LH, Henriksen TB: Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes. Arch Pediatr Adolesc Med 2009; 163:949-954
6. Wisner KL, Sit DK, Hanusa BH, et al: Major depression and antidepressant treatment: Impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009; 166:557-566
7. Huang H, Coleman S, Bridge JA, et al: A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of pretermbirthandlowbirthweight.GenHospPsychiatry2014; 36:13-18
8. Grzeskowiak LE, Gilbert AL, Morrison JL: Neonatal outcomes after late-gestation exposure to selective serotonin reuptake inhibitors. J Clin Psychopharmacol 2012; 32:615-621
9. Toh S, Mitchell AA, Louik C, et al: Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction. J Clin Psychopharmacol 2009; 29:555-560
10. Palmsten K, Hernández-Díaz S, Huybrechts KF, et al: Use of antidepressants near delivery and risk of postpartumhemorrhage: Cohort study of lowincomewomen in theUnited States. BMJ2013; 347:f4877
11. Koren G, Boucher N: Adverse effects in neonates exposed to SSRIs and SNRI in late gestation: Motherisk Update 2008. Can J Clin Pharmacol 2009; 16:e66-e67
12. Levinson-Castiel R, Merlob P, Linder N, et al: Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors interminfants.ArchPediatrAdolescMed2006; 160:173-176
13. Moses-Kolko EL, Bogen D, Perel J, et al: Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: Literature reviewand implications for clinical applications. JAMA 2005; 293:2372-2383
14. Kieler H, Artama M, Engeland A, et al: Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: Population based cohort study from the five Nordic countries. BMJ 2012; 344:d8012
15. Källén B, Olausson PO: Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008; 17:801-806
16. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al: Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006; 354:579-587
17. Masand PS, Gupta S: Selective serotonin-reuptake inhibitors: An update. Harv Rev Psychiatry 1999; 7:69-84
18. Melville JL, Gavin A, Guo Y, et al: Depressive disorders during pregnancy: Prevalence and risk factors in a large urban sample. Obstet Gynecol 2010; 116:1064-1070
19. Grote NK, Bridge JA, Gavin AR, et al: A meta-analysis of depression during pregnancyand the risk of preterm birth, low birthweight, and intrauterine growth restriction. Arch Gen Psychiatry 2010; 67: 1012-1024
20. Nordeng H, van Gelder MM, Spigset O, et al: Pregnancy outcome after exposure to antidepressants and the role of maternal depression: Results from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2012; 32:186-194
21. Oberlander TF, WarburtonW,Misri S, et al: Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006; 63:898-906
22. Martikainen J, Pajunen R, Saastamoinen L, et al: Finnish Statistics on Medicines 2009. Joint publication of the Finnish Medicines Agency and the Social Insurance Institution in Finland. Tampere, Juvenes Print and Tampereen Yliopistopaino Oy, 2010. http://www.kela.fi/in/internet/suomi.nsf/NET/210503131819PN
23. GisslerM,Shelley J: Quality of data on subsequent events in a routine Medical Birth Register. Med Inform Internet Med 2002; 27:33-38
24. Sankilampi U, Hannila ML, Saari A, et al: New population-based references for birth weight, length, and head circumference in singletons and twins from 23 to 43 gestation weeks. Ann Med 2013; 45:446-454
25. Koren G, Madjunkova S, Maltepe C: The protective effects of nausea and vomiting of pregnancy against adverse fetal outcome: A systematic review. Reprod Toxicol 2014; 47:77-80
26. Saigal S, DoyleLW:Anoverviewof mortalityand sequelae of preterm birth from infancy to adulthood. Lancet 2008; 371:261-269
27. Wadhwa PD, Entringer S, Buss C, et al: The contribution of maternal stress to preterm birth: Issues and considerations. Clin Perinatol 2011; 38:351-384
28. Lupattelli A, Spigset O, Koren G, et al: Risk of vaginal bleeding and postpartum hemorrhage after use of antidepressants in pregnancy: A study from the Norwegian Mother and Child Cohort Study. J Clin Psychopharmacol 2014; 34:143-148
29. Andrade C, Sandarsh S, Chethan KB, et al: Serotonin reuptake inhibitor antidepressants and abnormal bleeding: A review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2010; 71:1565-1575
30. Palmsten K, Huybrechts KF, Michels KB, et al: Antidepressant use and risk for preeclampsia. Epidemiology 2013; 24:682-691
31. Malm H, Artama M, Gissler M, et al: Selective serotonin reuptake inhibitors and risk for major congenital anomalies. Obstet Gynecol 2011; 118:111-120
32. Furu K, Kieler H, Haglund B, et al: Selective serotonin reuptake inhibitors and venlafaxine in early pregnancy and risk of birth defects: Population based cohort study and sibling design.BMJ2015; 350:h1798
33. Koren G, Finkelstein Y, Matsui D, et al: Diagnosis and managementof poor neonatal adaptation syndrome in newborns exposed in utero to selective seretonin/norepinephrine reuptake inhibitors. J Obstet Gynaecol Can 2009; 31:348-350
34. Hanley GE, Mintzes B: Patterns of psychotropic medicine use in pregnancy in the United Statesfrom2006to 2011amongwomenwith private insurance. BMC Pregnancy Childbirth 2014; 14:242
35. Garn JV, Nagulesapillai T, Metcalfe A, et al: International Comparison of Common Risk Factors of Preterm Birth Between the US and Canada, Using PRAMS and MES (2005-2006). Matern Child Health J 2014; 19:811-818
36. Sund R: Quality of the Finnish Hospital Discharge Register: A systematic review. Scand J Public Health 2012; 40:505-515
37. Hebert KK, Cummins SE,Hernández S, et al: Currentmajor depression among smokers using a state quitline. Am J Prev Med 2011; 40:47-53